The overexpression of CXCR4 in breast cancer cells resulted in increased bone metastasis formation [113], whereas CXCR4 inhibition significantly reduced metastatic burden in an experimental model of prostate cancer bone metastasis [127]. Here, CXCR4 is linked to prostate carcinoma.